This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Beloueche-Babari, M. Articles by Ronen, S. M. Search for Related Content PubMed PubMed Citation Articles by Beloueche-Babari, M. Articles by Ronen, S. M.

Magnetic Resonance Spectroscopy Monitoring of Mitogen-Activated Protein Kinase Signaling Inhibition

¹ Cancer Research UK Clinical Magnetic Resonance Research Group, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton and ² Cancer Research UK Centre for Cancer Therapeutics, Institute of Cancer Research, Sutton, Surrey, United Kingdom

Requests for reprints: Mounia Beloueche-Babari, Cancer Research UK Clinical Magnetic Resonance Research Group, Institute of Cancer Research, and Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey SM2 5PT, United Kingdom. Phone: 44-208-661-3738; Fax: 44-208-661-0846; E-mail: Mouniab{at}icr.ac.uk.

Several mitogen-activated protein kinase (MAPK) signaling inhibitors are currently undergoing clinical trial as part of novel mechanism-based anticancer treatment strategies. This study was aimed at detecting biomarkers of MAPK signaling inhibition in human breast and colon carcinoma cells using magnetic resonance spectroscopy. We investigated the effect of the prototype MAPK kinase inhibitor U0126 on the ³¹P-MR spectra of MDA-MB-231, MCF-7 and Hs578T breast, and HCT116 colon carcinoma cells. Treatment of MDA-MB-231 cells with 50 µmol/L U0126 for 2, 4, 8, 16, 24, 32, and 40 hours caused inhibition of extracellular signal–regulated kinases (ERK1/2) phosphorylation from 2 hours onwards. ³¹P-MR spectra of extracted cells indicated that this was associated with a significant drop in phosphocholine levels to 78 ± 8% at 8 hours, 74 ± 8% at 16 hours, 66 ± 7% at 24 hours, 71 ± 10% at 32 hours, and 65 ± 10% at 40 hours post-treatment. In contrast, the lower concentration of 10 µmol/L U0126 for 40 hours had no significant effect on either P-ERK1/ 2 or phosphocholine levels in MDA-MB-231 cells. Depletion of P-ERK1/2 in MCF-7 and Hs578T cells with 50 µmol/L U0126 also produced a drop in phosphocholine levels to 51 ± 17% at 40 hours and 23 ± 12% at 48 hours, respectively. Similarly, in HCT116 cells, inhibition with 30 µmol/L U0126 caused depletion of P-ERK1/2 and a decrease in phosphocholine levels to 80 ± 9% at 16 hours and 61 ± 4% at 24 hours post-treatment. The reduction in phosphocholine in MDA-MB-231 and HCT116 cells correlated positively with the drop in P-ERK1/2 levels. Our results show that MAPK signaling inhibition with U0126 is associated with a time-dependent decrease in cellular phosphocholine levels. Thus, phosphocholine has potential as a noninvasive pharmacodynamic marker for monitoring MAPK signaling blockade.

This article has been cited by other articles:

				M. Beloueche-Babari, J. C. Peak, L. E. Jackson, M.-Y. Tiet, M. O. Leach, and S. A. Eccles Changes in choline metabolism as potential biomarkers of phospholipase C{gamma}1 inhibition in human prostate cancer cells Mol. Cancer Ther., May 1, 2009; 8(5): 1305 - 1311. [Abstract] [Full Text] [PDF]

				J. Ross, A. M. Najjar, M. Sankaranarayanapillai, W. P. Tong, K. Kaluarachchi, and S. M. Ronen Fatty acid synthase inhibition results in a magnetic resonance-detectable drop in phosphocholine Mol. Cancer Ther., August 1, 2008; 7(8): 2556 - 2565. [Abstract] [Full Text] [PDF]

				D. Sachdev and D. Yee Disrupting Insulin-Like Growth Factor Signaling as a Potential Cancer Therapy Am. Assoc. Cancer Res. Educ. Book, April 12, 2008; 2008(1): 39 - 58. [Abstract] [Full Text] [PDF]

				W. M. Claudino, A. Quattrone, L. Biganzoli, M. Pestrin, I. Bertini, and A. Di Leo Metabolomics: Available Results, Current Research Projects in Breast Cancer, and Future Applications J. Clin. Oncol., July 1, 2007; 25(19): 2840 - 2846. [Abstract] [Full Text] [PDF]

				D. Sachdev and D. Yee Disrupting insulin-like growth factor signaling as a potential cancer therapy Mol. Cancer Ther., January 1, 2007; 6(1): 1 - 12. [Abstract] [Full Text] [PDF]

				C. Guo, G. Wu, J. L. Chin, G. Bauman, M. Moussa, F. Wang, N. M. Greenberg, S. S. Taylor, and J. W. Xuan Bub1 Up-Regulation and Hyperphosphorylation Promote Malignant Transformation in SV40 Tag-Induced Transgenic Mouse Models Mol. Cancer Res., December 1, 2006; 4(12): 957 - 969. [Abstract] [Full Text] [PDF]

				P. Workman, E. O. Aboagye, Y.-L. Chung, J. R. Griffiths, R. Hart, M. O. Leach, R. J. Maxwell, P. M. J. McSheehy, P. M. Price, and J. Zweit Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies. J Natl Cancer Inst, May 3, 2006; 98(9): 580 - 598. [Abstract] [Full Text] [PDF]

				M. Sankaranarayanapillai, W. P. Tong, D. S. Maxwell, A. Pal, J. Pang, W. G. Bornmann, J. G. Gelovani, and S. M. Ronen Detection of histone deacetylase inhibition by noninvasive magnetic resonance spectroscopy Mol. Cancer Ther., May 1, 2006; 5(5): 1325 - 1334. [Abstract] [Full Text] [PDF]

				N. Shah, A. Sattar, M. Benanti, S. Hollander, and L. Cheuck Magnetic Resonance Spectroscopy as an Imaging Tool for Cancer: A Review of the Literature J Am Osteopath Assoc, January 1, 2006; 106(1): 23 - 27. [Abstract] [Full Text] [PDF]

				M. Beloueche-Babari, L. E. Jackson, N. M.S. Al-Saffar, S. A. Eccles, F. I. Raynaud, P. Workman, M. O. Leach, and S. M. Ronen Identification of magnetic resonance detectable metabolic changes associated with inhibition of phosphoinositide 3-kinase signaling in human breast cancer cells Mol. Cancer Ther., January 1, 2006; 5(1): 187 - 196. [Abstract] [Full Text] [PDF]

				P. WORKMAN Drugging the Cancer Kinome: Progress and Challenges in Developing Personalized Molecular Cancer Therapeutics Cold Spring Harb Symp Quant Biol, January 1, 2005; 70(0): 499 - 515. [Abstract] [PDF]